Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
149 hedge funds and large institutions have $491M invested in Progenics Pharmaceuticals Inc in 2018 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 64 increasing their positions, 32 reducing their positions, and 26 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 32
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 155 → 149 (-6)
6% less capital invested
Capital invested by funds: $522M → $491M (-$31.1M)
17% less call options, than puts
Call options by funds: $7.33M | Put options by funds: $8.83M
19% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$27.8M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$23.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$18.3M |
| 4 |
BlackRock
New York
|
+$14.6M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$7.87M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$4.44M |
| 3 |
Morgan Stanley
New York
|
-$3.32M |
| 4 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$2.52M |
| 5 |
PA
Pinnacle Associates
New York
|
-$1.99M |
PGNX Hedge Fund Activity: Q3 2018 in Review
149 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q3 2018, worth a combined $491M — down 6% from $522M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of PGNX and 21 opened new positions — a net loss of 5 holders — while 32 trimmed existing stakes and 64 added.
The largest buyer was Armistice Capital, adding an estimated $27.8M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $7.87M sold.
- 149 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q3 2018, down from 155 in Q2 2018.
- Funds reported $491M of Progenics Pharmaceuticals Inc stock for Q3 2018, down 6% quarter-over-quarter.
- 21 funds opened new Progenics Pharmaceuticals Inc positions in Q3 2018 and 26 closed out, a net change of -5 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q3 2018 was Armistice Capital, an estimated $27.8M added.
- The largest Progenics Pharmaceuticals Inc seller in Q3 2018 was Baker Bros. Advisors, an estimated $7.87M sold.
Based on aggregated 13F filings for Q3 2018.